Statement: the primary clinical trial and the secondary clinical trial do not document any cardiac or infection-related adverse events, but epilepsy instances are noted in both
Primary_evidence: Adverse Events 1:   Total: 0/655 (0.00%) Adverse Events 2:   Total: 0/580 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/15 (0.00%) Adverse Events 2:   Total: 0/16 (0.00%)